[Therapeutic approaches to cerebral blood flow disorders].
Heiss
W D
WD
D000138:Acidosis / Q000628:therapy; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D001809:Blood Viscosity / Q000187:drug effects; D001929:Brain Edema / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D003911:Dextrans / Q000627:therapeutic use; D006438:Hemodilution; D006801:Humans; D007036:Hypothermia, Induced; D007773:Lactates / Q000378:metabolism; D009270:Naloxone / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D001463:Barbiturates; D002121:Calcium Channel Blockers; D003911:Dextrans; D007773:Lactates; D014665:Vasodilator Agents; D002245:Carbon Dioxide; D009270:Naloxone
Ansatzpunkte zur Therapie zerebraler Durchblutungsstörungen.